Nordion to manufacture NAV5001 agent for clinical trials

05/16/2013 | Pharmaceutical Business Review Online

Nordion has inked a deal with Navidea Biopharmaceuticals, agreeing to manufacture the imaging agent NAV5001 for Navidea's Phase IIb and Phase III trials expected to start this year. The agent is used in diagnosing Parkinsonian syndromes and dementia with Lewy bodies. The deal is initially effective for three years.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park